Orion is planning to establish a new packaging and logistics centre in Salo. The company has signed a letter of intent with Nokia, according to which it would acquire premises from Nokia in Salo and centralise some of the packaging and logistics functions carried out in the pharmaceuticals plants in Espoo and Turku in these premises in Salo. If established, the centre would also create new jobs.
Due to increased production volumes, Orion is planning to centralise some of its pharmaceutical packaging and logistics functions in Salo in premises to be acquired from Nokia. According to a letter of intent signed by the companies, Orion would acquire production and storage space and establish a new packaging and logistics centre in these premises.
Adapting the premises to Orion's needs would start at the beginning of next year, and operations in the new premises would start approximately during 2013. The packaging and logistics centre would be functioning at full capacity in the autumn of 2014. If completed, the project would increase the number of Orion's personnel in Finland, and when ready, the centre would provide jobs approximately for over 100 people.
Orion has today started negotiations with personnel representatives regarding reorganisation of work. It is anticipated that in addition to the need to increase the number of personnel, it will be possible to provide each employee involved in the negotiations with a job in Salo, or at Orion's other business locations in Espoo and Turku, as a result of growing production volumes and personnel planning.
Nokia
Communications
Tel. 07180 34900
Email: press.services@nokia.com
Publisher:
Orion Corporation Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the Company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
Orion's production plants are all located in Finland: in Espoo, Turku, Oulu, Hanko and Kuopio.